Alternative promoter usage of the membrane glycoprotein CD36

por Andersen, Malin, Lenhard, Boris, Whatling, Carl, Eriksson, Per, Odeberg, Jacob
Publicado 2006

Ticagrelor Removal From Human Blood

por Angheloiu, George O., Gugiu, Gabriel B., Ruse, Cristian, Pandey, Rishikesh, Dasari, Ramachandra R., Whatling, Carl
Publicado 2017

Fractalkine has anti-apoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signalling

por White, Gemma E., Tan, Thomas C.C., John, Alison E., Whatling, Carl, McPheat, William L., Greaves, David R.
Publicado 2010

Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD

por Heerspink, Hiddo J.L., Law, Gordon, Psachoulia, Konstantina, Connolly, Kathleen, Whatling, Carl, Ericsson, Hans, Knöchel, Jane, Lindstedt, Eva-Lotte, MacPhee, Iain
Publicado 2021

Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo‐controlled, phase I study in healthy voluntee...

por Gan, Li‐Ming, Lagerström‐Fermér, Maria, Ericsson, Hans, Nelander, Karin, Lindstedt, Eva‐Lotte, Michaëlsson, Erik, Kjaer, Magnus, Heijer, Maria, Whatling, Carl, Fuhr, Rainard
Publicado 2019

Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects

por Knöchel, Jane, Nelander, Karin, Heijer, Maria, Lindstedt, Eva-Lotte, Forsberg, Gun-Britt, Whatling, Carl, Shimada, Hitoshi, Han, David S., Gabrielsen, Anders, Garkaviy, Pavlo, Ericsson, Hans
Publicado 2021

Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction

por Nelander, Karin, Lagerstrom‐Fermer, Maria, Amilon, Carl, Michaëlsson, Erik, Heijer, Maria, Kjaer, Magnus, Russell, Muir, Han, David, Lindstedt, Eva‐Lotte, Whatling, Carl, Gan, Li‐Ming, Ericsson, Hans
Publicado 2021

Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5‐Lipoxygenase Activating Protein Inhibitor

por Ericsson, Hans, Nelander, Karin, Lagerstrom‐Fermer, Maria, Balendran, Clare, Bhat, Maria, Chialda, Ligia, Gan, Li‐Ming, Heijer, Maria, Kjaer, Magnus, Lambert, John, Lindstedt, Eva‐Lotte, Forsberg, Gun‐Britt, Whatling, Carl, Skrtic, Stanko
Publicado 2018

The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids

por Prill, Sebastian, Caddeo, Andrea, Baselli, Guido, Jamialahmadi, Oveis, Dongiovanni, Paola, Rametta, Raffaela, Kanebratt, Kajsa P., Pujia, Arturo, Pingitore, Piero, Mancina, Rosellina Margherita, Lindén, Daniel, Whatling, Carl, Janefeldt, Annika, Kozyra, Mikael, Ingelman-Sundberg, Magnus, Valenti, Luca, Andersson, Tommy B., Romeo, Stefano
Publicado 2019

An integrative multiomic network model links lipid metabolism to glucose regulation in coronary artery disease

por Cohain, Ariella T., Barrington, William T., Jordan, Daniel M., Beckmann, Noam D., Argmann, Carmen A., Houten, Sander M., Charney, Alexander W., Ermel, Raili, Sukhavasi, Katyayani, Franzen, Oscar, Koplev, Simon, Whatling, Carl, Belbin, Gillian M., Yang, Jialiang, Hao, Ke, Kenny, Eimear E., Tu, Zhidong, Zhu, Jun, Gan, Li-Ming, Do, Ron, Giannarelli, Chiara, Kovacic, Jason C., Ruusalepp, Arno, Lusis, Aldons J., Bjorkegren, Johan L. M., Schadt, Eric E.
Publicado 2021